Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1996-04-12
1998-04-07
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
514279, 514283, A61K 8127
Patent
active
057361568
ABSTRACT:
The present invention provides water soluble, stable, highly pharmacologically active camptothecin drugs by solubilizing the camptothecin drugs in liposomes composed of lipids or in micelles composed of surfactants. The invention overcomes both the insolubility problems and instability problems of the drugs administered in their free form. The pH of the internal environment of the liposomes or micelles may be reduced pH which prevents hydrolysis of those camptothecin drugs which have lower affinity for the liposome or micelle membrane. Typically in the liposomes, the lactone ring of drug intercalates in between the lipid acyl chains, in a protected environment well removed from the aqueous interface. In this manner the lactone ring of the drug is stabilized and the biologically active form of camptothecin drugs are conserved.
REFERENCES:
patent: 4812312 (1989-03-01), Berestein
patent: 5145684 (1992-09-01), Liversidge
patent: 5552156 (1996-09-01), Burke
"The Role of Liposome Composition on the Stabilization of Ancitabine," Satish K. Pejaver et al., The Ohio State University, 1987, pp. 2633-2649.
Ostro. Liposomes, p. 277, 1987.
Szoka, Ann. Rev. Biophys. Bioeng., 9, 467, 1980.
"Liposomal Stabilization of Camptothecin's lactone Ring", Burke et al., Journal of American Chemical Society, 1992, p. 114.
"Liposomes for the Sustained Drug Release in Vivo", Blume et al., Biochimica et Biophysica Act, Elsevier Science Publishers, 1990, vol. 1029, pp. 91-97.
"Liposomes as Carriers of Antitumor Agents: Toward a Clinical Realty", R. Perez-Soler, Cancer Treatment Reviews, Academic Press Limited, 1989, vol. 16, pp. 67-82.
"Liposome Preparation and Size Characterization", by Woodle et al., Methods in Enzymology, Academic Press, Inc. 1989, vol. 171, pp. 193-217.
"Interactions of Liposomes with Mammalian Cells", Pagano et al., Ann. Rev. Biophys. Bioeng., Annual Reviews Inc., 1978, vol. 7, pp. 435-468.
"Liposomes", Lasic, Danilo, American Scientist, Jan.-Feb. 1992, vol. 80, pp. 20-31.
"Selective in Vivo Localization of Daunorubicin Small Unilamellar Vesicles in Solid Tumors", by Forssen et al., Cancer Research 52, pp. 3255-3261, Jun. 15, 1992.
"Influence of Vesicle Size, Lipid Composition, and Drug-to-Lipid Ratio on the Biological Activity of Liposomal Doxorubicin in Mice", Mayer et al., Cancer Research 49, Nov. 1, 1989, pp. 5922-5930.
"Microscopic Localization of Sterically Stabilized Liposomes in Colon Carcinoma-bearing Mice" Huang et al., Cancer Research 52, pp. 5135-5143, Oct. 1, 1992.
"Tumoricidal Effects of Liposomes Containing Phosphatidylinositol or Phosphatidylcholine" Jett et al., Methods in Enzymology, vol. 141, pp. 459-466, 1987.
"Influence of Lipid Composition on the Antitumor Activity Exerted by Doxorubicin-containing Liposomes in a Rat Solid Tumor Model" Storm et al., Cancer Research 47, pP. 3366-3372, Jul. 1, 1987.
"Liposome formulations with Prolonged Circulation Time in Blood and Enhanced Uptake by Tumors" Gabizon et al., Proc. Natl. Acad. Sci. USA vol. 85, pp. 6949-6953, Sep. 1988.
"Mixed Micelles as a Proliposomal Lymphotropic Drug Carrier" Supersaxo et al., Pharmaceutical Research, vol. 8, No. 10, pp. 1286-1291, 1991.
"Small Liposomes are better than Large Liposomes for Specific Drug Delivery in Vitro" Machy et al., Biochimica et Biophysica Acta, 730, pp. 313-320, 1983.
"Stealth Liposomes: An Improved Sustained Release System for 1-.beta.-D-Arabinofuranosylcytosine" Allen et al., Cancer Research 52, pp. 2431-2439, May 1, 1992.
"Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy" Papahadjopoulos et al., Proc. Natl. Acad. Sci. USA 88, pp. 11460-11464, Dec. 1991.
"Enhancement of Murine Tumor Cell Sensitivity to Adriamycin by Presentation of the Drug in Phosphatidylcholine-Phosphatidylserine Liposomes" Fan et al., Cancer Research 50, pp. 3619-3626, Jun. 15, 1990.
"Interaction of Positively-charged Liposomes with Blood: Implications for their application in vivo" Senior et al., Biochimica et Biophysica Act 1070, pp. 173-179, 1991.
"Effect of Liposome Composition and other Factors on the Targeting of Liposomes to Experimental Tumors: Biodistribution and Imaging Studies" Gabizon et al., Cancer Research 50, pp. 6371-6378, Oct. 1, 1990.
"Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues" Allen et al., Biochimica et Biophysica Acta 981, pp. 27-35, 1989.
"Liposome delivery of Antisense Oligonucleotides: Adsorption and Efflux characteristics of Phosphorothioate Oligodeoxynucleotides" by Akhtar et al., Journal of Controlled Release 22 (1992) 47-56.
"Modulation of Doxorubicin Resistance by Valinomycin (NSC 122023) and Liposomal Valinomycin in Chinese Hamster Ovary Cells" Daoud et al., Cancer Research 49, pp. 2661-2667, May 15 1989.
"Anti-Laminin Receptor Antibody Targeting of Liposomes with Encapsulated Doxorubicin to Human Breast Cancer Cells in Vitro" Rahman et al., Journal of National Cancer Institute 81, pp. 1794-1989, 1989.
"Phase I Clincal and Parmacological Study of Liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocylcohexane Platinum(II)" Perez-Soler et al., Cancer Research 50, pp. 4254-4259, 1990.
"Pharmacological, Toxicological and Therapeutic Evaluation in Mice of Doxorubicin Entrapped in Cardiolipin Liposomes" Rahman et al., Cancer Research 45, pp. 796-803, Feb. 1985.
"Method for Rapid Separation of Liposome-Associated Doxorubicin from Free Doxorubicin in Plasma" Thies et al., Analytical Biochemistry 188, pp. 65-71, 1990.
"Generation and Characterization of Iron-and Barium-loaded Liposomes" Chakrabarti et al., Biochimica et Biophysica Acta 1108, pp. 233-239, 1992.
"Augmentation of Antiproliferative Activity of Interferon Alfa Against Human Bladder Tumor Cell Lines by Encapsulation of Interferon Alfa Within Liposomes" Killion et al., Journal of National Cancer Institute vol. 81, No. 18, pp. 1387-1392, Sep. 20, 1989.
Pharmaceutical Dosage Forms Disperse Systems edited by Lieberman, Herbert A., pp. 334-338 from Chapter 8 "Surfactants" (1988) Marcel Kekker Inc.
"Complete Inhibition of Growth followed by Death of Human Malignant Melanoma Cells in Vitro and Regression of Human Melanoma Xenografts in Immunodeficient Mice Induced by Captothecins" Pantazis et al., Cancer Research 52, pp. 3980-3987, Jul. 15, 1992.
"DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts" Giovanella et al., Science 246, pp. 1046-1048, Nov. 24, 1989.
"Complete Growth Inhibition of Human Cancer Xenografts in Nude Mice by Treatment with 20-(S)-Camptothecin" by Giovanella et al., Cancer Research 51, pp. 3052-3055, Jun. 1. 1991.
"Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Unites In Vitro" Burris et al., Journal of National Cancer Institute 84, No. 23, pp. 1816-1820, Dec. 2, 1992.
Ch. 8 "Surfactants", by Martin M. Rieger from Pharmaceutical Dosage Formes edited by Herbert Lieberman, (1988) pp. 334-338.
"Separation of Liposome-Associated Doxorubicin from Non-Liposome-Associated Doxorubicin in Human Plasma" by Druckman, et al., Biochimia et Biophysica Act, 980 (1989) pp. 381-384.
"Mixed Micelles in Drug Delivery" by Danilo D. Lasic, Nature, vol. 355, Jan. 16, 1992 pp. 272-280.
"Model Studies Directed Toward the Boron-Neutron Capture Therapy of Cancer", by Shelly, et al. Proc. Natl. Acad. Sci. USA, vol. 89, pp. 9030-9043, Oct. 1992.
"Rapid Separation of Low Molecular Weight Solutes from Liposomes without Dilution" Analytical Biochemistry, 90, pp. 809-815 (1978). by Fry, et al.
"Improved Therapeutic Benefits of Doxorubicin by Entrapment in Anionic Liposomes" by Forssen, et al. Cancer Research, 43, pp. 546-550, Feb. 1983.
"Stable Target-Sensitive Immunoliposomes" by Pinnaduwage, et al., Biochemistry, 32, pp. 2850-2855 1992.
"Liposome-Mediated Delivery of Gadolinium-Diethylenetraminopentaacetic Acid to Hepatic Cells", by Vion-Dury, et al., J. Pharm. and Exp. Therapeutics, 253, No. 3, pp. 1113-1118.
"Effective detergent/lipid ratios in the Solubulization of Phosphatidylcholine Vesicles by Triton X-100", by Partearroyo, et at., FE
Kishore Gollamudi S.
The Ohio State University
LandOfFree
Liposomal anf micellular stabilization of camptothecin drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liposomal anf micellular stabilization of camptothecin drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal anf micellular stabilization of camptothecin drugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-10480